CorMedix CRMD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 92.9%0.0pp | 92.9%— | —— | 94.3%+72.3pp | |
| Operating margin | 48.2%— | —— | —— | -46,819.9%-31,402pp | |
| Net margin | 52.3%— | —— | —— | -45,409.9%-30,635pp | |
| Returns | |||||
| Return on equity | 66.6%— | —— | -74%-23.6pp | -50.4%+2.3pp | |
| Return on invested capital | 97.4%— | —— | -248%+22.3pp | -270.3%+171pp | |
| Efficiency | |||||
| Asset turnover | 0.7×+0.2× | 0.4×— | —— | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 2.1×-1.3× | 3.4×-3.6× | 7×-2.5× | 9.4×-3.0× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.9×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $5.05+251% | $1.44+4.4% | $1.38+0.8% | $1.37-18.0% | |
| Valuation | |||||
| Market capitalization | $605.65M-34.4% | $491.49M+138% | $206.09M+18.3% | $174.21M+0.5% | |
| Price / earnings | 3.4×— | —— | —— | —— | |
| Price / sales | 1.5×-9.6× | 11.3×— | —— | 2,663.4×+1,756× | |
| Price / book | 1.4×-6.6× | 5.8×+2.9× | 2.9×-0.2× | 3.2×+0.4× | |
| EV / EBITDA | 4.7×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CorMedix's profit margins?
- CorMedix (CRMD) runs a 91.9% gross margin and a 48.4% operating margin, with a 45.2% net margin.
- Where do CorMedix's ratios come from?
- Every ratio is computed from CorMedix's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
